PMID- 36329806
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20221105
IS  - 1178-7007 (Print)
IS  - 1178-7007 (Electronic)
IS  - 1178-7007 (Linking)
VI  - 15
DP  - 2022
TI  - Research Progress of Duodenal-Jejunal Bypass Liner in the Treatment of Obesity 
      and Type 2 Diabetes Mellitus.
PG  - 3319-3327
LID - 10.2147/DMSO.S382324 [doi]
AB  - With the development of economy and improvement of people's living standards, the 
      incidence of obesity and type 2 diabetes mellitus (T2DM) has increased 
      significantly and obesity has also become one of the most important risk factors 
      of T2DM. In light of these trends, there have been many ways to take effect in 
      losing weight. However, they also have corresponding deficiencies including 
      inapparent curative effect, complex and incomplete reversible procedures and 
      severe complications. Duodenal-Jejunal Bypass Liner (DJBL), which mimics 
      Roux-en-Y gastric bypass (RYGB), is proved to play a key role in weight loss and 
      control of T2DM. DJBL is reversible, less invasive and is more suitable for the 
      treatment of obesity and T2DM, which is associated with multiple mechanisms, 
      including incretin effect, gastric emptying mechanism, bile acid regulation, 
      intestinal microbiota, inflammatory reaction mechanism and neural mechanism. In 
      our review, we aimed to elaborate DJBL's clinical efficacy, safety and mechanisms 
      in detail.
CI  - (c) 2022 Chen et al.
FAU - Chen, Ji-Hua
AU  - Chen JH
AD  - Department of Gastroenterology and Hepatology, Tianjin Medical University General 
      Hospital, Tianjin, People's Republic of China.
AD  - Tianjin Institute of Digestive Disease, Tianjin Medical University General 
      Hospital, Tianjin, People's Republic of China.
FAU - Yu, Zi-Han
AU  - Yu ZH
AD  - Department of Gastroenterology and Hepatology, Tianjin Medical University General 
      Hospital, Tianjin, People's Republic of China.
AD  - Tianjin Institute of Digestive Disease, Tianjin Medical University General 
      Hospital, Tianjin, People's Republic of China.
FAU - Liu, Qin-Ling Fei
AU  - Liu QF
AD  - Department of Gastroenterology and Hepatology, Tianjin Medical University General 
      Hospital, Tianjin, People's Republic of China.
AD  - Tianjin Institute of Digestive Disease, Tianjin Medical University General 
      Hospital, Tianjin, People's Republic of China.
FAU - Meng, Qing-Guo
AU  - Meng QG
AD  - Department of Gastroenterology and Hepatology, Tianjin Medical University General 
      Hospital, Tianjin, People's Republic of China.
AD  - Tianjin Institute of Digestive Disease, Tianjin Medical University General 
      Hospital, Tianjin, People's Republic of China.
FAU - Chen, Xin
AU  - Chen X
AD  - Department of Gastroenterology and Hepatology, Tianjin Medical University General 
      Hospital, Tianjin, People's Republic of China.
AD  - Tianjin Institute of Digestive Disease, Tianjin Medical University General 
      Hospital, Tianjin, People's Republic of China.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20221028
PL  - New Zealand
TA  - Diabetes Metab Syndr Obes
JT  - Diabetes, metabolic syndrome and obesity : targets and therapy
JID - 101515585
PMC - PMC9624146
OTO - NOTNLM
OT  - Roux-en-Y gastric bypass
OT  - duodenal-jejunal bypass liner
OT  - obesity
OT  - type 2 diabetes mellitus
COIS- The authors declare that they have no conflict of interest.
EDAT- 2022/11/05 06:00
MHDA- 2022/11/05 06:01
PMCR- 2022/10/28
CRDT- 2022/11/04 02:17
PHST- 2022/07/14 00:00 [received]
PHST- 2022/10/19 00:00 [accepted]
PHST- 2022/11/04 02:17 [entrez]
PHST- 2022/11/05 06:00 [pubmed]
PHST- 2022/11/05 06:01 [medline]
PHST- 2022/10/28 00:00 [pmc-release]
AID - 382324 [pii]
AID - 10.2147/DMSO.S382324 [doi]
PST - epublish
SO  - Diabetes Metab Syndr Obes. 2022 Oct 28;15:3319-3327. doi: 10.2147/DMSO.S382324. 
      eCollection 2022.